MC
ALXN

Mathes Company’s Alexion Pharmaceuticals ALXN Stock Holding History

Mathes Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1,600
Closed -$223K – 138
2016
Q1 		$223K Hold
1,600
– – 0.13% 118
2015
Q4 		$305K Hold
1,600
– – 0.17% 111
2015
Q3 		$250K Hold
1,600
– – 0.17% 113
2015
Q2 		$289K Hold
1,600
– – 0.15% 127
2015
Q1 		$277K Hold
1,600
– – 0.14% 139
2014
Q4 		$296K Hold
1,600
– – 0.15% 137
2014
Q3 		$265K Hold
1,600
– – 0.13% 144
2014
Q2 		$250K Hold
1,600
– – 0.12% 155
2014
Q1 		$243K Hold
1,600
– – 0.13% 152
2013
Q4 		$213K Buy
+1,600
New +$192K 0.11% 155

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return